Microneedle with Chitosan Adjuvant as an Alternative Method of Administration of COVID-19 Vaccination with Nucleocapsid Protein Targets


  • Sanchia Callista Raihanah Wiryawan Medical Student, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
  • Tafana Fadhillah Laili Medical Student, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
  • Vatine Adila Medical Student, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
  • Reyna Cesariyani Rahmadianti Rusuldi Medical Student, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
  • Alfian Nur Rosyid Department of Pulmonary and Respiratory Medicine, Faculty of Medicine and Hospital, Universitas Airlangga, Surabaya, Indonesia




COVID-19, SARS-CoV 2 protein, COVID-19 vaccination, Microneedles COVID-19 vaccination, Chitosan adjuvant, Chitosan allergy, Infection disease


Background: Researchers had been contriving to develop vaccines as a way to eradicate the COVID-19 pandemic. Several vaccines had been inaugurated with the intramuscular administration (IM) route, which has a higher risk of a shoulder injury. Microneedle, an alternative administration route that had been studied, showed more advantages compared to IM. Besides, chitosan as an adjuvant was also studied to increase immune response. This study aimed to explore further the use of microneedle as a method of COVID-19 vaccine administration with chitosan as adjuvants and nucleocapsid as vaccine target due to their benefits in the future.

Aims: This literature review was assembled by exploring and analysing various studies of our topic from several sources, which accounted for 24 studies.

Results: A potential vaccination target was spike protein due to its essential role in binding to ACE2 for virus entry into target cells. However, due to the large number of vaccinations targeting spike protein and many mutations, research about vaccination with nucleocapsid protein as the target was carried out. COVID-19 vaccine targeting nucleocapsid proteins exhibited a robust immune response even stronger than spike protein by dot blot analysis, and microneedles target SARS-CoV-2 nucleocapsid protein has a balanced ratio of IgG1 and IgG2A nucleocapsid antibodies that are essential for virus extermination. The use of chitosan as an adjuvant helped reduce the dose of vaccine and the risk of allergy.

Conclusion: Vaccine administration through microneedles, chitosan as an adjuvant, and nucleocapsid as vaccine target had the potential to be an alternative, especially in a pandemic situation.


Download data is not yet available.


Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov [Internet]. 2020; 19(5):305–6. Available from: http://dx.doi.org/10.1038/d41573-020-00073-5

World Health Organization. Novel Coronavirus (2019-nCoV) SITUATION REPORT - 1 [Internet]. Switzerland: WHO; 2020 [cited 2021 March 18]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4

Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020; 11(29): 1–13.

Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and modern vaccines. Eur Rev Med Pharmacol Sci. 2021; 25(3):1663–79.

AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine [Internet]. Who.int. 2021 [cited 4 August 2021]. Available from: https://www.who.int/publications/m/item/chadox1-s-recombinant-covid-19-vaccine

Chuaychoosakoon C, Parinyakhup W, Tanutit P, Maliwankul K, Klabklay P. Shoulder injury related to Sinovac COVID-19 vaccine: A case report. Ann Med Surg [Internet]. 2021; 68 (July):102622. Available from: https://doi.org/10.1016/j.amsu.2021.102622

O’Shea J, Prausnitz MR, Rouphael N. Dissolvable microneedle patches to enable increased access to vaccines against SARS-CoV-2 and future pandemic outbreaks. Vaccines. 2021; 9(4):1–9.

Dutta NK, Mazumdar K, Gordy JT. The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development. J Virol. 2020; 94 (13).

Tsang H, Chan L, Cho W, Yu A, Yim A, Chan A et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Review of Anti-infective Therapy. 2020; 19 (7):877-888.

Khalaj-Hedayati A. Protective Immunity against SARS Subunit Vaccine Candidates Based on Spike Protein: Lessons for Coronavirus Vaccine Development. Journal of Immunology Research. 2020; 2020.

Kuwentrai C, Yu J, Zhang BZ, Hu YF, Dou Y, Gong HR, et al. Induction of Humoral and Cellular Immunity by Intradermal Delivery of SARS-CoV-2 Nucleocapsid Protein Using Dissolvable Microneedles. J Immunol Res. 2021; 2021.

Smits VAJ, Hernández-Carralero E, Paz-Cabrera MC, Cabrera E, Hernández-Reyes Y, Hernández-Fernaud JR, et al. The Nucleocapsid protein triggers the main humoral immune response in COVID-19 patients. Biochem Biophys Res Commun. 2021; 543: 45–9.

Kwon K, Lim S, Choi S, Kim D, Jin H, Jee G et al. Microneedles: quick and easy delivery methods of vaccines. Clinical and Experimental Vaccine Research. 2017; 6(2):156.

Tuan-Mahmood T, McCrudden M, Torrisi B, McAlister E, Garland M, Singh T et al. Microneedles for intradermal and transdermal drug delivery. European Journal of Pharmaceutical Sciences [Internet]. 2013 [cited 21 March 2021]; 50(5):623-637. Available from: http://doi:10.1016/j.ejps.2013.05.005

Guillot A, Cordeiro A, Donnelly R, Montesinos M, Garrigues T, Melero A. Microneedle-Based Delivery: An Overview of Current Applications and Trends. Pharmaceutics [Internet]. 2020 [cited 21 March 2021]; 12 (6):569. Available from: http://doi:10.3390/pharmaceutics12060569

Kim E, Erdos G, Huang S, Kenniston TW, Balmert SC, Carey CD, et al. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine. 2020; 55:1–12.

Kuwentrai C, Yu J, Rong L, Zhang BZ, Hu YF, Gong HR, et al. Intradermal delivery of receptor-binding domain of SARS-CoV-2 spike protein with dissolvable microneedles to induce humoral and cellular responses in mice. Bioeng Transl Med. 2021; 6(1):1–9.

Chen M, Lai K, Ling M, Lin C. Acta Biomaterialia Enhancing immunogenicity of antigens through sustained intradermal delivery using chitosan microneedles with a patch-dissolvable design. Acta Biomater [Internet]. 2018; 65:66–75. Available from: https://doi.org/10.1016/j.actbio.2017.11.004

Bal SM, Slütter B, Verheul R, Bouwstra JA, Jiskoot W. Adjuvanted, antigen-loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: Adjuvant- and site-dependent immunogenicity in mice. Eur J Pharm Sci [Internet]. 2012; 45(4):475–81. Available from: http://dx.doi.org/10.1016/j.ejps.2011.10.003

Hayashi Y, Yamada S, Yanagi Guchi K, Koyama Z, Ikeda T. Chitosan and Fish Collagen as Biomaterials for Regenerative Medicine [Internet]. 1st ed. Vol. 65, Advances in Food and Nutrition Research. Elsevier Inc.; 2012. 107–120 p. Available from: http://dx.doi.org/10.1016/B978-0-12-416003-3.00006-8

Waibel KH, Haney B, Moore M, Whisman B, Gomez R. Safety of chitosan bandages in shellfish allergic patients. Mil Med. 2011; 176(10):1153–6.

Dong L, Wichers HJ, Govers C. Beneficial health effects of chitin and chitosan. Chitin Chitosan Prop Appl. 2019; 145–67.

Jiang T, Ji H, Zhang L, Wang Y, Zhou H. Chitosan Oligosaccharide Exerts Anti-Allergic Effect against Shrimp Tropomyosin-Induced Food Allergy by Affecting Th1 and Th2 Cytokines. Int Arch Allergy Immunol. 2019; 180(1):10–6.

Bae MJ, Shin HS, Kim EK, Kim J, Shon DH. Oral administration of chitin and chitosan prevents peanut-induced anaphylaxis in a murine food allergy model. Int J Biol Macromol [Internet]. 2013; 61:164–8. Available from: http://dx.doi.org/10.1016/j.ijbiomac.2013.06.017



How to Cite

Sanchia Callista Raihanah Wiryawan, Tafana Fadhillah Laili, Vatine Adila, Reyna Cesariyani Rahmadianti Rusuldi, & Alfian Nur Rosyid. (2022). Microneedle with Chitosan Adjuvant as an Alternative Method of Administration of COVID-19 Vaccination with Nucleocapsid Protein Targets. Indonesian Archives of Biomedical Research, 2(1), 1–8. https://doi.org/10.55392/indarcbiores.v2i1.26